Popular Trials
Behavioral Intervention
Exercise Program for Pediatric Pulmonary Hypertension
"This trial aims to help children and teenagers with pulmonary hypertension (PH) be more active and improve their muscle strength. Previous studies have shown that children with PH are less active and have weaker muscles compared to
Oxygen Saturation Target for Newborn Pulmonary Hypertension
This trial tests if keeping oxygen levels higher (95-99%) is better than slightly lower (91-95%) for newborns with lung problems. It aims to find the best oxygen range to help them breathe better and reduce lung pressure.
Prostacyclin Analogue
Inhaled Treprostinil for Sarcoidosis
This trial is testing an inhaled medication called treprostinil for people with a specific lung disease (sarcoidosis) that causes high blood pressure in the lungs. The treatment aims to help these patients breathe better and exercise more easily by widening their lung blood vessels. The study will also check if this treatment is safe for them. Inhaled treprostinil has been shown to improve exercise tolerance and has demonstrated safety and beneficial effects on hemodynamics, exercise capacity, and quality of life.
Popular Filters
Trials for PH Patients
Sotatercept for Pulmonary Hypertension
This trial tests sotatercept, a medication aimed at improving heart and lung function in adults with a specific type of heart failure. It works by reducing resistance in lung blood vessels, helping the heart pump blood more easily.
Biguanide
Metformin for Pulmonary Hypertension
This trial is testing whether the diabetes drug metformin can improve outcomes in people with PH-HFpEF. The study will look at how well metformin works compared to placebo and what the effects are on heart function and capacity.
Angiogenic Cell Therapy
Angiogenic Cell Therapy for Pulmonary Hypertension
This trial is testing whether a treatment involving a person's own cells, transfected with human eNOS, is effective and safe for patients with severe PAH who are already on other PAH-targeted therapies.
Trials for Right Ventricular Dysfunction Patients
Biguanide
Metformin for Pulmonary Hypertension
This trial is testing whether the diabetes drug metformin can improve outcomes in people with PH-HFpEF. The study will look at how well metformin works compared to placebo and what the effects are on heart function and capacity.
Device
Aria CV System for Pulmonary Arterial Hypertension
This trial is testing a new device called the Aria CV PH System, which helps manage high blood pressure in the lungs and supports heart function. It is aimed at patients with pulmonary hypertension and related heart issues. The study will check if the device is safe and effective over a period of several months to a few years.
Trials With No Placebo
Computerized Decision Support for Pulmonary Hypertension
This trial will test whether or not an electronic health record alert will increase echocardiographic screening for CTEPH and the diagnosis of CTEPH in patients with prior pulmonary embolism and symptoms/signs suggestive of pulmonary hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms.
Procedure
TIVUSâ„¢ System for Pulmonary Hypertension
This trial will study the safety and effectiveness of the TIVUSâ„¢ System for treating pulmonary artery hypertension. Up to 15 patients will be enrolled in this prospective, open-label study at 4 centers.
Prostacyclin Analogue
Inhaled Treprostinil for Pulmonary Hypertension
This trial is testing an inhaled medication called treprostinil on patients with a lung condition that makes it hard for them to exercise. The medication helps by improving blood flow in the lungs. Researchers want to see if it makes exercise easier and improves quality of life after a period of use. Treprostinil has been shown to improve exercise capacity and is more convenient due to its longer-lasting effects.
View More Related Trials
Frequently Asked Questions
Introduction to pulmonary hypertension
What are the top hospitals conducting pulmonary hypertension research?
When it comes to the complex and often misunderstood condition of pulmonary hypertension, several hospitals are leading the way in cutting-edge clinical trials. In Boston, Massachusetts General Hospital stands out with four active trials dedicated to this challenging disease, along with a remarkable track record of 28 completed studies. Since initiating their first trial in 2002, they have been at the forefront of research and innovation for pulmonary hypertension treatment. Meanwhile, on the East Coast in Baltimore, the University of Maryland Medical Center has also made significant contributions with three ongoing trials and seven previously conducted ones since their debut study in 2012.
Traveling down south to Gainesville, Florida, we find that the University of Florida is making strides as well; currently conducting three active clinical trials focused on pulmonary hypertension while having successfully completed nine previous investigations since their inaugural trial began in 2006. Not far from there is Tufts Medical Center in Boston where researchers are actively engaged in three pivotal pulmonary hypertension clinical trials alongside completing twenty-seven other important research projects on this subject after starting off back almost two decades ago duringthe year2005.
Lastly but certainly not leastly,the University of Colorado Hospital locatedin Aurora continuescontributingto our understandingofpulmonaryhypertensionwiththreeactiveclinicaltrials.The noteworthy aspect hereis thatalthoughtherehaveonlybeenthreecompletedtrialssincetheirfirstinvestigationwasinitiatedin2017,thisinstitutionhas managedtomakea significantsplashinthefieldanddemonstratetheirexpertiseanddedicationtowardsthisseverelyunderdiagnosedcondition
As these top hospitals continue to push boundaries and explore new avenues for treating pulmonary hypertension patients worldwide can take comfort knowing that dedicated experts are tirelessly working towards improved outcomes and breakthroughs for this debilitating condition
Which are the best cities for pulmonary hypertension clinical trials?
When it comes to pulmonary hypertension clinical trials, several cities excel in conducting cutting-edge research. Los Angeles, California; Boston, Massachusetts; Indianapolis, Indiana; Houston, Texas; and Philadelphia, Pennsylvania are among the top cities with active trials. These studies focus on a range of experimental treatments such as Ralinepag, Sotatercept 0.3 mg/kg (escalating to 0.7 mg/kg), Macitentan, MK-5475, Selexipag, and Long Term Follow Up protocols. With their extensive involvement in ongoing research efforts for pulmonary hypertension treatment options, these cities offer individuals affected by this condition access to promising clinical trials that may lead to improved care outcomes.
Which are the top treatments for pulmonary hypertension being explored in clinical trials?
Pulmonary hypertension research is advancing, with a focus on exploring effective treatments in clinical trials. Leading the way is Ralinepag, currently being tested in two active trials for pulmonary hypertension. Since its introduction in 2018, it has been involved in three all-time clinical trials dedicated to this condition. Another promising contender is MK-5475, which recently made its debut and already has one ongoing trial for pulmonary hypertension among its three all-time trials. These innovative treatments hold promise for improving the lives of patients battling this challenging disease.
What are the most recent clinical trials for pulmonary hypertension?
Recent clinical trials offer hope for individuals with pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs. Among these trials is Hyperpolarized 129Xe, which has entered Phase 2 and shows promise as a potential treatment option. Additionally, AZD3427 Dose A and Treprostinil Palmitil have also progressed to Phase 2, providing further opportunities for advancing therapeutic interventions. These studies aim to improve our understanding and management of pulmonary hypertension, ultimately enhancing patient outcomes and quality of life.
What pulmonary hypertension clinical trials were recently completed?
Several notable clinical trials focusing on pulmonary hypertension have recently concluded, shedding light on potential advancements in the treatment of this condition. Actelion's trial for Selexipag reached completion in February 2021, offering insights into its effectiveness. Additionally, the University of Washington successfully completed a trial exploring the use of Famotidine 20 MG in May 2019. In January 2019, Northwell Health completed their investigation into Alteplase as a potential therapy for pulmonary hypertension. These recent trials contribute to our understanding and pave the way for further breakthroughs in combatting this challenging disease.